Drug intelligence / Profile preview

dexamethasone + ropivacaine

Development stage: Unknown
Lead developer: Heron Therapeutics
Modality: Small Molecules
Administration: Perineural Injection, Thoracic Paravertebral Injection, Fascia Iliaca Compartment Injection

Overview

A combination of dexamethasone (a corticosteroid) and ropivacaine (a local anesthetic) used for peripheral nerve blocks and regional anesthesia. This combination prolongs the duration of analgesia and enhances pain control after surgical procedures. Ropivacaine blocks sodium channels to prevent nerve impulse generation and conduction, while dexamethasone provides anti-inflammatory effects and extends the duration of the nerve block.

Other names: Combination of ropivacaine and dexamethasoneRopivacaine-dexamethasone combination

Targets

GR (Glucocorticoid receptor)SCN10A (Sodium channel protein type X alpha subunit)

Beyond the preview

Go deeper on dexamethasone + ropivacaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexamethasone + ropivacaine.

Explore the full profile